Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147536 · ClinicalTrials.gov registry record · Phase 2
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
A Phase 2 study, sponsored by Agenus.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01147536 is a Phase 2 study that was terminated before completion, run by Agenus. The registered enrollment target is 12 participants.
The verdict
NCT01147536, a Phase 2 study, was terminated before completion, sponsored by Agenus.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether participants exhibit a measurable immune response after multiple administrations of HSPPC-96 (heat shock protein-peptide complex 96), as assessed by enzyme linked immunosorbent spot (ELISPOT) assay.
Interventions
- BIOLOGICAL HSPPC-96
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147536
The ClinicalTrials.gov registry entry for NCT01147536 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HSPPC-96 is the first listed.
NCT01147536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147536 about?
NCT01147536 is a clinical study titled "Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence". The primary objective of the study is to determine whether participants exhibit a measurable immune response after multiple administrations of HSPPC-96 (heat shock protein-peptide complex 96), as assessed by enzyme linked immunosorbent spot (ELISPOT) assay.
What is the current status of trial NCT01147536?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2010-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01147536?
The interventions under investigation include: HSPPC-96 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01147536?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.